Double-blind study of the effect of selective serotonin reuptake inhabitor fluvoxamine on cognitive deficits in schizophrenia.

Trial Profile

Double-blind study of the effect of selective serotonin reuptake inhabitor fluvoxamine on cognitive deficits in schizophrenia.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2012

At a glance

  • Drugs Fluvoxamine (Primary)
  • Indications Schizophrenia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 08 Jun 2011 Status changed from active, no longer recruiting to completed.
    • 04 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top